EI
CERE

EAM Investors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

EAM Investors’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-39,907
Closed -$1.29M – 413
2021
Q4 		$1.29M Sell
39,907
-10,411
-21% -$367K 0.21% 237
2021
Q3 		$1.48M Sell
50,318
-4,703
-9% -$132K 0.25% 204
2021
Q2 		$1.41M Buy
+55,021
New +$788K 0.22% 251

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

EAM Investors's CERE Position: Q1 2022 in Review

EAM Investors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2022, closing a stake of 39,907 shares — an estimated $1.29M sold.

EAM Investors first reported a position in CERE in Q2 2021 and held it in 3 quarters. The position peaked at $1.48M in Q3 2021. 107 funds tracked by Wall St. Rank hold CERE as of Q1 2022.

  • EAM Investors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • EAM Investors sold 39,907 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2022, an estimated $1.29M.
  • EAM Investors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • EAM Investors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.48M in Q3 2021.
  • 107 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2022.

Based on EAM Investors's 13F filing for Q1 2022, filed 13 May 2022.